Latest Articles
-
Should You Buy Merck Stock After An Upbeat Q2?
Merck stock (NYSE: MRK), after an 8% fall in a month, underperforming the broader markets, with the S&P500 up 3%, appears to have room for growth. The company posted upbeat Q2 results this week, with solid growth for Keytruda and Gardasil. ...
-
How Has Merck Stock Performed During The 2022-23 Inflation Shock?
Merck stock (NYSE: MRK) currently trades at $110 per share, roughly 43% above its level in March 2021, and it looks fully valued. Merck saw its stock trading at around $91 in late June 2022, just before the Fed started increasing rates, and is ...
-
Is Merck Stock A Better Pick Over ABBV?
We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Merck stock (NYSE: MRK). MRK stock trades at a slightly higher valuation of 4.8x trailing revenues, compared to 4.2x for AbbVie, and this valuation gap will ...
-
Should You Buy Merck Stock At $120?
Merck stock (NYSE: MRK) is up 5% in a month, faring slightly better than the broader markets, with the S&P500 up 1%. Although the company posted upbeat Q1 results late last month, we believe MRK stock is fully valued. Merck’s revenue...
-
Earnings Beat In The Cards For Merck Stock?
Merck (NYSE: MRK) will report its Q1 2023 results on Thursday, April 27. We expect MRK stock to trade higher, with its revenue and earnings expected to be above the street estimates. Although the company should benefit from continued market sha...
-
Merck Stock Looks Better Priced Compared To Its Sector Peer
We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 4.7x trailing revenues vs. 10.5x for Eli Lilly. Although investors have assigned a high...
-
Here’s What To Expect From Merck’s Q4
Merck (NYSE: MRK) is scheduled to report its Q4 2022 results on Thursday, February 2. We expect MRK stock to trade sideways, with its revenue likely falling slightly below and earnings marginally above the street estimates. Although the company...
-
Pick Either Merck Stock Or Its Peer – Both May Offer Similar Returns
We believe that pharmaceutical giants Merck stock (NYSE: MRK) and Pfizer stock (NYSE: PFE) will likely offer similar returns over the next three years. Although Merck is trading at a comparatively higher valuation of 4.9x trailing revenues ...
-
Company Of The Day: Merck
What? Merck (NYSE:MRK) is preparing a new formulation for its blockbuster cancer immunotherapy Keytruda, which could be injected under the skin. Why? Keytruda will see patents start to expire in 2028. Merck believes that the new formulation h...
-
Is A Fall Imminent For Merck Stock After A 12% Rise In A Month?
Merck stock (NYSE: MRK) is up 12% in a month, outperforming the broader S&P500 index, up 5%. The rise in MRK stock can be attributed to the upbeat Q3 earnings it reported in late October. Its top and bottom line were well above our estimat...
-
Will Merck Stock Rise After Its Q3 Results?
Merck (NYSE: MRK) is scheduled to report its Q3 2022 results on Thursday, October 27. We expect the company to post mixed results, with revenue falling short and earnings slightly above the consensus estimate. Although the company should benefi...
-
Merck Stock Is Likely A Better Pick Over Its Peer
We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 3.9x trailing revenues vs. 10.8x for Eli Lilly. Investors have assigned a higher P/S mu...
-
Is Humira Maker A Better Bet Over Merck Stock?
We believe that AbbVie stock (NYSE: ABBV) is currently a better pick than its peer Merck stock (NYSE: MRK), given its better growth prospects. Both companies are comparable in valuation, with AbbVie trading at 4.2x, trailing revenues, and M...
-
Should You Buy Merck Stock After An Upbeat Q2?
Merck stock (NYSE: MRK) reported its Q2 results last week, with revenue and earnings comfortably above ours and the street estimates. However, MRK stock has seen a fall of around 4% in a week, with rising concerns over the drug pricing bill. A...
-
Will Merck Stock Rise After Its Q2 Results?
Merck (NYSE: MRK) is scheduled to report its Q2 2022 results on Thursday, July 28. We expect the company to have a robust Q2, with revenue falling in-line and earnings expected to be slightly above the consensus estimates, driven by a continued...
